# MI Profile

Source: https://onco.cc/drugs/caris-mi-profile/  
OnCo record `caris-mi-profile` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Caris Life Sciences' tissue test that reads every gene's DNA and RNA and stains for tumour proteins, offered outside the United States and Europe.

## Summary

MI Profile is Caris Life Sciences' tissue profiling test for solid tumours. It combines whole-exome and whole-transcriptome sequencing of more than 23,000 genes with immunohistochemistry for more than 25 tumour proteins, and reports single-nucleotide variants, insertions and deletions, copy number changes, microsatellite instability and tumour mutational burden. Two AI signatures are added for particular cases: Caris GPSai for cancer of unknown primary and Caris FOLFIRSTai for metastatic colorectal cancer. Caris gives an average turnaround of 6 to 9 days from receipt of the sample. Caris states that MI Profile is available globally excluding the United States, the European Economic Area, the EU and Switzerland; its FDA-approved tissue test in the United States is MI Cancer Seek.

## Fields

- Kind: Test
- Status: established
- Last checked: 2026-11-03
- Also known as: Caris MI Profile
- Tags: test
- Brand: MI Profile
- Modality: Tumour profiling test (whole exome, whole transcriptome and immunohistochemistry)
- Mechanism: Whole-exome DNA and whole-transcriptome RNA sequencing of more than 23,000 genes from formalin-fixed tumour tissue, with immunohistochemistry for more than 25 tumour proteins and, for some tumour types, chromogenic in situ hybridisation, pyrosequencing and AI-based signatures.

## Notes

- What a result means: the report lists alterations linked to approved drugs, signatures that bear on immunotherapy, and matching trials; Caris attaches a trial-matching service to every report.

## Sources

- Caris Life Sciences: MI Profile: https://www.carislifesciences.com/physicians/physician-tests/mi-profile/

## Connected records

- drugs: [MI Cancer Seek](https://onco.cc/drugs/caris-mi-cancer-seek/)
- biomarkers: [1p/19q codeletion](https://onco.cc/biomarkers/1p19q-codeletion-readout/), [BRAF fusion or rearrangement](https://onco.cc/biomarkers/braf-fusion/), [FGFR2 fusion or rearrangement](https://onco.cc/biomarkers/fgfr2-fusion-rearrangement/), [FGFR3 alteration (mutation or fusion)](https://onco.cc/biomarkers/fgfr3-alteration/), [H3 K27M mutation](https://onco.cc/biomarkers/h3-k27m/), [HER2 IHC 3+ (HER2-positive by immunohistochemistry)](https://onco.cc/biomarkers/her2-ihc-3-plus/), [HRD-positive (genomic instability score)](https://onco.cc/biomarkers/hrd-positive/), [MET amplification (gene copy number)](https://onco.cc/biomarkers/met-amplification-readout/), [MET exon 14 skipping mutation](https://onco.cc/biomarkers/met-ex14/), [MGMT promoter methylation](https://onco.cc/biomarkers/mgmt-promoter-methylation/), [MYCN amplification](https://onco.cc/biomarkers/mycn-amp/), [NRG1 gene fusion](https://onco.cc/biomarkers/nrg1-fusion/), [NTRK1/2/3 gene fusion](https://onco.cc/biomarkers/ntrk-fusion/), [PD-L1 CPS (combined positive score)](https://onco.cc/biomarkers/pd-l1-cps/), [PDGFRA exon 18 mutation (D842V)](https://onco.cc/biomarkers/pdgfra-exon-18-d842v/), [PTEN alteration (sequencing) and PTEN loss (IHC)](https://onco.cc/biomarkers/pten-alteration/), [TP53 mutation and del(17p)](https://onco.cc/biomarkers/tp53-del17p/)
- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- companies: [Caris Life Sciences](https://onco.cc/companies/caris/)
- terms: [Immunohistochemistry (IHC)](https://onco.cc/terms/ihc/), [Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)](https://onco.cc/terms/msi/), [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/), [Tumour mutational burden (TMB)](https://onco.cc/terms/tmb/)

---
JSON: https://onco.cc/api/v1/entities/caris-mi-profile.json